Servier
Worldwide

Healthcare
Professionals

Servier
Medical Art

Career
Opportunities

Patient
Information

Home

Index

Search

Contact

Site map

Home > Index

Index

Synomia Search

K

Q

X

Z

A

ABPM (Ambulatory blood pressure monitoring)

ACC (acetyl-CoA carboxylase)

Action in Diabetes and in Vascular disease

Active treatment

AI (Aortic Index)

American Society

AMI (anterior myocardial infarction)

Angina patients

Angina pectoris

Antianginal agent

Antianginal effects

Antianginal efficacy

Antidepressant efficacy

Antidepressant treatments

Antifracture efficacy

ARB (angiotensin receptor blocker)

Arterial stiffness

ASCOT-BPLA trial

Atherosclerotic plaque

Attached References

B

Baseline characteristics

BEAUTIFUL study

Blood pressure reduction

Blood pressure regulation

Bone mineral density

Bone remodeling

Bone resorption

Bone turnover in favor of formation

BP (brachial PP)

C

CAFE (Conduit Artery Function Evaluation)

Cardiac hypertrophy

Cardiac Outcomes

Cardiac remodeling

Cardioprotective effect

Cardiovascular outcomes

Cardiovascular protection

CASS (Coronary Artery Surgery Study)

CDT (catheter-directed thrombolysis)

CHD (coronary heart disease)

Chronic failure

Chronic heart failure

Chronic venous disease

Chronic venous disorders

Clinical acceptability

Clinical fracture

Clinical outcomes

Clinical vertebral fracture

Cognitive function

Collaborative Group

Concomitant use

Congestive heart failure

Conventional treatment

Coronary artery disease

Coronary syndrome

Creatinine clearance

D

DAFLON 500 mg

Death from causes

Department of Medicine

Depressed patients

Diabetic hypertensives

DIAMICRON MR

Diastolic dysfunction

Diastolic heart failure

Dilated cardiomyopathy

Dopamine agonist

Double-blind placebo-controlled study

Double-blind trial

Dr Jacques Servier

Dual mode of action

E

Early combination

Early treatment

Effects of trimetazidine

Efficacy in hypertensive patients

Elderly hypertensive patients

Elderly patients

Elevated heart rate

Endothelial function

Energy metabolism

Epidemiological studies

Estrogen deficiency

European Society of Cardiology

European Society of Hypertension

Exercise duration

Exercise tolerance

F

FFA (free fatty acids)

Fixed combination

Flavonoid fraction

G

Gene expression

Glucose oxidation

Glycemic control

GSVs (great saphenous vein)

H

Healthy volunteers

Heart failure patients

Heart rate reduction

Hemodynamic agents

Hemorrhoidal disease

High blood pressure

High heart rate

Hippocampal volume

Hospitalization for heart failure

Hyperium's efficacy

Hypertensive patients

Hypothalamic-pituitaryadrenal (HPA)

I

Ie (ischemic episodes)

Imidazoline receptors

Incorporated company of SERVIER

Inflammatory efficacy

Inflammatory property

Innovative formulation

Intensive glucose

Intensive group

International guidelines

International journals

International Osteoporosis Foundation

International study

International trial

Intervention studies

Ischemic cardiomyopathy

Ischemic effects

Ischemic efficacy

J

L

Life expectancy

Local treatment

Low-dose combination

LVM (left ventricular mass)

M

Major depression

Medicinal products

Member of the Editorial Boards

Member of the Editorial Boards of Journal

Metabolic agent

Metabolic mechanism of action

Modifiable factors

Modifiable risk factors

Multicenter trial

Myocardial oxygen consumption

N

NATRILIX SR

Natriuretic peptide

New-onset diabetes

New vertebral fracture

Nonmicronized diosmin

Nonvertebral fractures

Normalization rate

O

Oral administration

Osteoclast differentiation

Osteoclast formation

Osteoporotic fractures

Osteoporotic women

P

Parallel groups

Parkinson-CONTROL study

Parkinsonian patients

Parkinson's disease

Patient information

Patients with chronic stable angina

Patients with renal failure

Patients with stable angina

Pharmaceutical company

Placebo-controlled study

Placebo-controlled trial

Plaque disruption

Postmenopausal osteoporosis

Postmenopausal osteoporotic women

Post-MI patients

Powerful antihypertensive

Powerful antihypertensive efficacy

PRETERAX strategy

Prevalent fracture

Product description

Professor of Medicine

Progression of disease

Protective effect

Publications of interest

Pulmonary edema

Pulmonary embolism

Pure heart rate reduction

Purified flavonoid fraction

R

RANKL (receptor activator of NF-kB ligand)

Reduction in events

Reduction in heart rate

Reduction in mortality

Reference drugs

Respiratory mucosa

Risk of hip fractures

Risk of mortality

Risk of nonvertebral fractures

S

Sequential monotherapy

Serious complications

Servier Fellowship

Servier Medical Art

Significant increase

SOTI (Spinal Osteoporosis Therapeutic Intervention)

SPA (spontaneous platelet aggregation)

SR (sustained-release)

Stable coronary artery disease

Stages of disease

Strontium ranelate

Study population

Systolic and diastolic blood pressure

T

Total exercise duration

Treatment group

Treatment of angina

Treatment of heart failure

U

Unique properties

UPDRS III score

V

Vastarel MR

VAS (visual analog scale)

Venous disorders

Venous hypertension

Ventricular dysfunction

Ventricular ejection fraction

Ventricular function

Ventricular remodeling

Vertebral fracture

W

Y

© 2008 LES LABORATOIRES SERVIER,
an incorporated company of SERVIER
All Rights Reserved - Terms of Use

SERVIER does not sell its products over the Internet - More information